Back to first-pass browser

First-pass extracted concept

gene-based interventions for skeletal muscle atrophy

Candidate: concept label1 source documents4 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

antioxidant gene delivery, CRISPR editing, Nrf2 activation, RNA modulators

Evidence Snippets

Gene-based interventions, including antioxidant gene delivery, Nrf2 activation, RNA modulators, and CRISPR editing, offer new avenues but remain limited by safety and delivery barriers.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1mechanistic pathophysiologysupports2026Source 1DOIPubMed

Neuromuscular junction destabilization, excitation-contraction coupling defects, and mitochondrial dysfunction intensify calcium dysregulation and promote reactive oxygen and nitrogen species accumulation in skeletal muscle atrophy.

Quoted textsource-backed
Skeletal muscle atrophy emerges from intertwined neuromuscular and metabolic failures, in which neuromuscular junction destabilization, excitation contraction coupling defects, and mitochondrial dysfunction collectively intensify calcium dysregulation and drive the accumulation of reactive oxygen and nitrogen species (RONS)
Claim 2mechanistic pathophysiologysupports2026Source 1DOIPubMed

RONS-mediated activation of NF-kB and FOXO pathways accelerates ubiquitin-proteasome and autophagy-lysosome degradation, contributing to motor unit loss.

Quoted textsource-backed
RONS-mediated activation of NF-baB and FOXO pathways accelerates ubiquitin proteasome and autophagy lysosome degradation, leading to motor unit loss.
Claim 3therapeutic rationalemixed2026Source 1DOIPubMed

Gene-based interventions including antioxidant gene delivery, Nrf2 activation, RNA modulators, and CRISPR editing are promising for skeletal muscle atrophy but are limited by safety and delivery barriers.

Quoted textsource-backed
Gene-based interventions, including antioxidant gene delivery, Nrf2 activation, RNA modulators, and CRISPR editing, offer new avenues but remain limited by safety and delivery barriers.
Claim 4translational strategysupports2026Source 1DOIPubMed

Translational progress in skeletal muscle atrophy therapy requires rigorous safety pipelines, mechanistic biomarkers of motor unit recovery, and modular combination regimens integrating cells, genes, scaffolds, and rehabilitative input.

Quoted textsource-backed
Translational progress requires rigorous safety pipelines, mechanistic biomarkers of motor unit recovery, and modular combination regimens that integrate cells, genes, scaffolds, and rehabilitative input.